Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 8, 2013, Pages 1965-1972

  Salvado, M Dolores ^a   Di Gennaro, Antonio ^a   Lindbom, Lennart ^a   Agerberth, Birgitta ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Antimicrobial cationic peptides; Cyclooxygenase 1; Endothelium; LL 37 peptide, human

Indexed keywords

ACETYLSALICYLIC ACID; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PHOSPHOLIPASE A2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; NEOVASCULARIZATION (PATHOLOGY); PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANGIOGENESIS; ANTIMICROBIAL CATIONIC PEPTIDES; CYCLOOXYGENASE 1; ENDOTHELIUM; LL-37 PEPTIDE, HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; ASPIRIN; CALCIUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOTHELIAL CELLS; GROUP IV PHOSPHOLIPASES A2; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PRIMARY CELL CULTURE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; SIGNAL TRANSDUCTION;

EID: 84881025135     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301851     Document Type: Article

References (29)

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473: 298-307.
2. Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012;18: 233-243.
3. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23: 2840-2855.
4. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345: 433-442.
5. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353: 2373-2383.
6. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2004;101: 591-596.
7. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002;62: 506-511.
8. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282: 11613-11617.
9. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30: 131-141.
10. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sørensen OE, Borregaard N, Rabe KF, Hiemstra PS. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol. 2003;171: 6690-6696.
11. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175: 4662-4668.
12. De Yang, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192: 1069-1074.
13. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111: 1665-1672.
14. Soehnlein O, Wantha S, Simsekyilmaz S, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Trans Med. 2011;3: 1-10.
15. Carretero M, Escámez MJ, García M, Duarte B, Holguín A, Retamosa L, Jorcano JL, Río MD, Larcher F. In vitro and in vivo wound healingpromoting activities of human cathelicidin LL-37. J Invest Dermatol. 2008;128: 223-236.
16. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL, Scandurro AB. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A. 2009;106: 3806-3811.
17. Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z, Sandstedt B, Rotstein S, Mentaverri R, Sánchez F, Pivarcsi A, Ståhle M. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res. 2009;11:R6.
18. von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, Reimer D, Wiewrodt R, Biesterfeld S, Aigner A, Czubayko F, Bals R. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2008;59: 12-23.
19. Salvado MD, Alfranca A, Escolano A, Haeggström JZ, Redondo JM. COX-2 limits prostanoid production in activated HUVECs and is a source of PGH2 for transcellular metabolism to PGE2 by tumor cells. Arterioscler Thromb Vasc Biol. 2009;29: 1131-1137.
20. Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K, Xu Q, Yan ZQ. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26: 1551-1557.
21. Barlow PG, Li Y, Wilkinson TS, Bowdish DM, Lau YE, Cosseau C, Haslett C, Simpson AJ, Hancock RE, Davidson DJ. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol. 2006;80: 509-520.
22. Sørensen O, Cowland JB, Askaa J, Borregaard N. An ELISA for hCAP- 18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods. 1997;206: 53-59.
23. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377: 31-41.
24. Wan M, Godson C, Guiry PJ, Agerberth B, Haeggström JZ. Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J. 2011;25: 1697-1705.
25. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S, Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003;197: 221-232.
26. Amano H, Ito Y, Suzuki T, Kato S, Matsui Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, Hayashi I, Satoh Y, Narumiya S, Majima M. Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase- 9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci. 2009;100: 2318-2324.
27. Finetti F, Donnini S, Giachetti A, Morbidelli L, Ziche M. Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway. Circ Res. 2009;105: 657-666.
28. Chamorro CI, Weber G, Grönberg A, Pivarcsi A, Ståhle M. The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol. 2009;129: 937-944.
29. Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, Wu K, Yu J, Sung JJ, Cho CH. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer. 2010;127: 1741-1747.